Acutaas Chemicals Limited reported a 43.0% YoY increase in revenue for Q3 FY26, reaching ₹3,932 million. Profit After Tax (PAT) also saw a significant surge, crossing ₹1,000 million and reaching ₹1,062 million, a 133.7% YoY increase. The company is revising its revenue growth guidance upward from 25% to approximately 30%.
Strong Financial Performance
Acutaas Chemicals Limited announced its financial results for the third quarter and nine months ended December 31, 2025, showcasing robust growth. Key highlights from the announcement include:
-
Revenue from Operations: Increased by 43.0% year-over-year (YoY) to ₹3,932 million in Q3 FY26.
-
Gross Profit: Rose by 76.1% YoY to ₹2,240 million, with a gross margin of 57.0%.
-
EBITDA: Climbed significantly by 119.4% YoY to ₹1,507 million, resulting in an EBITDA margin of 38.3%.
-
Profit After Tax (PAT): Experienced substantial growth, reaching ₹1,062 million, which is a 133.7% increase compared to the previous year.
Growth Drivers and Future Outlook
Mr. Naresh Patel, Executive Chairman & Managing Director of Acutaas Chemicals Limited, commented on the results, stating the company’s focus on reinforcing its core pharmaceutical intermediates business and scaling battery and semiconductor chemicals verticals. These businesses are expected to operate as independent growth engines, contributing significantly to the company’s overall topline. The company is experiencing strong growth momentum driven by the continued ramp-up of its CDMO business.
Revised Revenue Guidance
Supported by a healthy order book and improved visibility, Acutaas Chemicals is revising its revenue growth guidance upward—from 25% to approximately 30%.
Source: BSE
